Yahoo Finance

Organon Secures FDA Approval Extending NEXPLANON Use to Five Years

Organon & Co. OGN recently announced that the FDA has approved a supplemental New Drug Application, extending the duration of use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque to up to five ...
Times Argus

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Proper training prior to first use of NEXPLANON can minimize the risk of improper NEXPLANON insertion. Because of the risk of complications due to improper insertion and removal NEXPLANON is available ...
Nasdaq

FDA Approves Organon's SNDA Extending NEXPLANON Use To Five Years With New REMS Program

(RTTNews) - Organon (OGN) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for NEXPLANON (etonogestrel implant). NEXPLANON is ...
Seeking Alpha

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US ...